Effects of comedication on the serum levels of aripiprazole: Evidence from a routine therapeutic drug monitoring service

Pharmacopsychiatry

Volumn 40, Issue 3, 2007, Pages 107-110

  Castberg, I ^a,b,c   Spigset, O ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Department of Forensic Psychiatry Brøset ^*  (Norway)

Author keywords

Aripiprazole; Drug interactions; Therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; ESCITALOPRAM; LAMOTRIGINE; LITHIUM; VALPROIC ACID;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG PROTEIN BINDING; ENZYME INHIBITION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MONOTHERAPY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; VALPROIC ACID;

EID: 34250358362     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-977715     Document Type: Article

References (18)

1. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affective Disord 2005; 86: 99-104
2. Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11: 275-283
3. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005; 45: 89-93
4. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychitary 2005; 66: 49-51
5. Dickens M, Chen C. Lamotrigine, Chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors, Antiepileptic drugs. Philadelphia: Lippincott Williams & Wilkins, 2002; 370-379
6. El-Sayeh H, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004; CD004578.pub2
7. El-Sayeh H, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006; CD004578
8. Grander G, Kugel M, Ebrecht M, Gorocs T, Modell S. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl 1): 21-25
9. Hiemke C, Draqievic A, Grunder G, Hatter S, Sachse J, Vernaleken I et al. Therapeutic drug monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160
10. http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 18494
11. Kane JM, Carson WH, Saha AR, McQuade RD, Ingento GG, Zimbroff DL et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771
12. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM et al. For the aripiprazole study group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637
13. Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55-64
14. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44: 179-187
15. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16: 779-786
16. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833-838
17. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326-1330
18. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109